Sirtex Medical: Biotech Market Spotlight
Friday, 23 October, 2009
Oncology treatment company, Sirtex Medical (ASX:SRX) has continued to perform well, gaining 23c or 3.85% today as of 3pm to $6.20.
This follows a week of strong gains following an announcement on Monday of a 68% increase in operating profit from $3.25 million to $5.47 million for the last financial quarter.
The company also announced a dividend of 2c per share plus a special dividend of 5c per share to be paid in December.
Sirtex Medical, which manufactures SIR-Spheres for the treatment of liver cancer, saw revenues raise from $12.29 million to $16.47 million in the last quarter, a lift of 34%, in spite of a strengthening Australian dollar.
The company's stock has performed well over since the start of the year, with it seeing a 280% lift since January 2.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
